CRIS Current Research Information System

AMABILE, MARILINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.898
AS - Asia 2.486
EU - Europa 2.133
AF - Africa 159
SA - Sud America 103
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 7.783
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.871
VN - Vietnam 677
CN - Cina 676
SG - Singapore 591
GB - Regno Unito 506
SE - Svezia 353
DE - Germania 278
IT - Italia 268
FR - Francia 147
HK - Hong Kong 133
IN - India 124
UA - Ucraina 108
NL - Olanda 105
JP - Giappone 102
RU - Federazione Russa 94
BR - Brasile 75
IE - Irlanda 66
TG - Togo 56
FI - Finlandia 43
CI - Costa d'Avorio 40
KR - Corea 40
ZA - Sudafrica 36
EE - Estonia 32
CH - Svizzera 31
JO - Giordania 31
BG - Bulgaria 22
BE - Belgio 21
CA - Canada 20
GR - Grecia 17
PL - Polonia 15
TR - Turchia 14
BD - Bangladesh 13
AR - Argentina 12
IR - Iran 12
PH - Filippine 12
TH - Thailandia 12
IQ - Iraq 9
SC - Seychelles 9
ES - Italia 8
NG - Nigeria 8
SA - Arabia Saudita 7
MY - Malesia 6
TW - Taiwan 6
AT - Austria 5
CL - Cile 5
PY - Paraguay 5
ID - Indonesia 4
KE - Kenya 4
MX - Messico 4
PK - Pakistan 4
EC - Ecuador 3
IL - Israele 3
LT - Lituania 3
AU - Australia 2
CO - Colombia 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
LB - Libano 2
PS - Palestinian Territory 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BY - Bielorussia 1
CY - Cipro 1
EG - Egitto 1
HN - Honduras 1
HR - Croazia 1
JM - Giamaica 1
MA - Marocco 1
MN - Mongolia 1
NE - Niger 1
NO - Norvegia 1
SV - El Salvador 1
TN - Tunisia 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.783
Salva come PNG Salva come JPEG
Città #
Southend 443
Singapore 411
Ashburn 302
Chandler 295
Fairfield 269
Woodbridge 141
Dong Ket 138
Houston 137
Wilmington 130
Seattle 129
Hong Kong 122
Hefei 114
Ho Chi Minh City 114
San Jose 114
Ann Arbor 107
Dallas 104
Beijing 97
Hanoi 93
Cambridge 90
Tokyo 85
Princeton 84
Jacksonville 71
Dublin 66
Santa Clara 64
Boardman 63
Lomé 56
New York 53
Helsinki 42
Nanjing 42
Lauterbourg 40
Westminster 40
Abidjan 39
Padova 37
Turin 36
Los Angeles 34
Seoul 33
Bologna 31
Amman 30
Berlin 26
Bern 25
Jinan 25
Buffalo 24
Milan 23
Munich 23
Da Nang 22
Frankfurt am Main 21
Saint Petersburg 21
Sofia 21
Brussels 19
Falkenstein 17
Haiphong 17
Bremen 16
Shenyang 16
Changsha 15
Guangzhou 14
Orem 14
San Diego 14
Warsaw 14
Rome 13
Falls Church 12
Hebei 12
Tianjin 12
Hangzhou 11
Medford 11
Taizhou 11
Washington 11
Bengaluru 10
Haikou 10
Nanchang 10
Dearborn 9
Des Moines 9
Florence 9
Phoenix 9
The Dalles 9
Zhengzhou 9
Can Tho 8
Düsseldorf 8
Jiaxing 8
Redondo Beach 8
Amsterdam 7
Chengdu 7
Istanbul 7
Mahé 7
Mumbai 7
Mülheim 7
San Giovanni in Persiceto 7
Toronto 7
Xi'an 7
Abeokuta 6
Boston 6
Redmond 6
São Paulo 6
Verona 6
Yubileyny 6
Bangkok 5
Chandigarh 5
Chicago 5
Hải Dương 5
Johannesburg 5
Leawood 5
Totale 5.021
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 351
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 300
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 289
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 283
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 273
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 257
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 252
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 242
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 239
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 223
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 205
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 203
Patient-reported outcome measures (PROMs) after elective hip, knee and shoulder arthroplasty: Protocol for a prospective cohort study 199
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 193
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 192
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 186
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. 181
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 179
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. 176
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 174
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 173
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 167
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 166
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 166
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 166
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 166
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 157
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 157
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION 150
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 140
Identifying patient subgroups with different trends of patient-reported outcomes (PROMs) after elective knee arthroplasty 135
Patient-reported outcomes in patients undergoing elective arthroplasty: the PaRIS-IOR study 127
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients 126
Overexpression of FBP1 is Associated to High Sokal Risk in Chronic Myeloid Leukemia Patients. 125
New drugs to overcome meccanisms of resistance in Ph+ leukemia: Bosutinib 124
Results of high-dose imatinib mesylate in intermediate SOKAL risk chronic myeloid leukemia patients in early chronic phase: A phase II trial of the GIMEMA CML WP 122
Molecular monitoring of acute myeloid leukemia associated with inv(16): Threshold of CBFβ/MYH11 transcript copy number above which relapse occurs and below which continuous complete remission is likely (multiple letters) [8] 117
The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. 110
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome 103
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure 93
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. 88
null 79
null 77
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC 73
Modelling longitudinal health-related constructs: A latent variable approach 59
Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia 58
null 57
Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia-positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24-homology domains but not the pleckstrin homology one 48
Totale 7.926
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.539
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.539
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021331 0 0 0 0 0 0 0 0 0 37 47 247
2021/2022924 102 13 56 106 79 68 18 52 35 83 160 152
2022/20231.088 125 217 55 140 56 91 36 48 174 20 89 37
2023/2024393 10 49 19 50 29 129 30 27 8 10 20 12
2024/20251.001 30 109 67 87 141 63 75 40 2 133 40 214
2025/20262.136 199 186 305 135 287 129 177 83 463 172 0 0
Totale 7.926